Product Name: RON (1235-1241) pY1238
Product Number: PE-04BBD00
Size: 200 µg      Price:30.00
1 mg      $US60.00
Peptide Name: RON (1235-1241) pY1238

Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases and for epitope mapping of phosphosite-specific antibodies. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. Y1238 phosphorylation stimulates phosphotransferase activity.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: DRE-pY-YSV

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Amide

Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 1009.93 Da

Peptide Purity Percent after Synthesis and Purification: >80

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Storage Stability: stable

Scientific Background: RON (MST1R) is a protein-tyrosine kinase of the TK group and Met family. It is a receptor kinase that binds macrophage stimulating factor 1 (MST1, MSF) to propagate a cell migration, survival, or differentiation signal. This kinase is highly expressed and widely distributed in most tested human tissues. Phosphorylation of RON at Y1198 and Y1288 increases phosphotransferase activity. Phosphorylation at S1394 induces interaction with 14-3-3 beta. RON interacts with the HYAL2 receptor protein, rendering it functionally inactive. HYAL2 is a candidate tumour-suppressor glycosylphosphatidylinositol-anchored cell-surface protein that serves as an entry receptor for jaagsiekte retrovirus, a virus that causes contagious lung cancer in sheep that is morphologically similar to human bronchioloalveolar carcinoma. It was shown that RON liberated from the association with HYAL2 becomes functionally active and activates the Akt and mitogen-activated protein kinase pathways. RON has also been linked with the development of breast, head and neck, ovarian, renal and breast cancers, and pulmonary adenomas.